Loading...
XNASCGEN
Market cap143mUSD
Dec 24, Last price  
1.60USD
1D
5.26%
1Q
-8.05%
Jan 2017
-68.63%
Name

Compugen Ltd

Chart & Performance

D1W1MN
XNAS:CGEN chart
P/E
—
P/S
4.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.65%
Rev. gr., 5y
13.45%
Revenues
33m
+346.12%
4,027,000646,000215,000180,000338,000250,0001,115,000-424,000242,0003,549,00012,367,0009,277,000712,000017,800,00002,000,0006,000,0007,500,00033,459,000
Net income
-19m
L-44.34%
-13,722,000-13,978,000-13,020,000-12,114,000-12,527,000-3,831,000-7,203,000-12,004,000-13,628,000-14,083,000-11,094,000-20,163,000-31,506,000-37,066,000-22,599,000-27,337,000-27,260,000-32,873,000-33,694,000-18,754,000
CFO
-36m
L+4.00%
-12,202,000-11,108,000-9,933,000-8,407,000-10,012,000-7,453,000-4,279,000-9,249,000-10,846,000-6,439,000-11,148,000-25,607,000-19,819,000-30,658,000-13,291,000-27,888,000-28,320,000-22,750,000-34,506,000-35,886,000
Earnings
Mar 03, 2025

Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
URL
https://cgen.com/
IPO date
Aug 01, 2000
Employees
69
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
33,459
346.12%
7,500
25.00%
6,000
200.00%
Cost of revenue
46,451
42,874
41,074
Unusual Expense (Income)
NOPBT
(12,992)
(35,374)
(35,074)
NOPBT Margin
Operating Taxes
8,970
58
(1,330)
Tax Rate
NOPAT
(21,962)
(35,432)
(33,744)
Net income
(18,754)
-44.34%
(33,694)
2.50%
(32,873)
20.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,081
353
14,958
BB yield
-1.78%
-0.57%
-4.13%
Debt
Debt current
632
613
768
Long-term debt
2,070
3,237
4,732
Deferred revenue
25,392
2,715
Other long-term liabilities
3,398
3,265
6,392
Net debt
(47,983)
(79,858)
(112,262)
Cash flow
Cash from operating activities
(35,886)
(34,506)
(22,750)
CAPEX
(172)
(487)
(292)
Cash from investing activities
35,510
37,060
6,616
Cash from financing activities
3,081
353
16,838
FCF
(59,409)
(34,885)
(33,166)
Balance
Cash
50,685
83,708
117,762
Long term investments
Excess cash
49,012
83,333
117,462
Stockholders' equity
(474,278)
(455,533)
(421,840)
Invested Capital
569,978
538,403
540,390
ROIC
ROCE
EV
Common stock shares outstanding
87,633
86,556
84,204
Price
1.98
176.65%
0.72
-83.36%
4.30
-64.49%
Market cap
173,514
180.10%
61,948
-82.89%
362,077
-62.43%
EV
125,531
(17,910)
249,815
EBITDA
(12,516)
(34,892)
(34,613)
EV/EBITDA
0.51
Interest
31
27
25
Interest/NOPBT